Asthma & COPD--IQPC's Second Conference.

Idrugs Pub Date : 2010-09-01
Matthew C Catley
{"title":"Asthma & COPD--IQPC's Second Conference.","authors":"Matthew C Catley","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The International Quality & Productivity Center's (IQPC) Second Asthma & COPD conference, held in Philadelphia, included topics covering new therapeutic developments in the field of asthma and COPD. This conference report highlights selected presentations on mAb treatments for asthma, including targeting IL-5, IL-13, IL-9 and TNFa, CCR3 inhibitors, histamine H4 receptor inhibition, novel mouse models of COPD and inhaled antisense asthma therapies. Investigational drugs discussed include mepolizumab (GlaxoSmithKline plc), benralizumab (BioWa Inc/Kyowa Hakko Kirin Co Ltd/MedImmune LLC), AMG-317 (Amgen Inc/Takeda Bio Development Center Ltd), TPI-ASM-8 (Pharmaxis Ltd) and AIR-645 (Altair Therapeutics Inc).</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 9","pages":"601-4"},"PeriodicalIF":0.0000,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Idrugs","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The International Quality & Productivity Center's (IQPC) Second Asthma & COPD conference, held in Philadelphia, included topics covering new therapeutic developments in the field of asthma and COPD. This conference report highlights selected presentations on mAb treatments for asthma, including targeting IL-5, IL-13, IL-9 and TNFa, CCR3 inhibitors, histamine H4 receptor inhibition, novel mouse models of COPD and inhaled antisense asthma therapies. Investigational drugs discussed include mepolizumab (GlaxoSmithKline plc), benralizumab (BioWa Inc/Kyowa Hakko Kirin Co Ltd/MedImmune LLC), AMG-317 (Amgen Inc/Takeda Bio Development Center Ltd), TPI-ASM-8 (Pharmaxis Ltd) and AIR-645 (Altair Therapeutics Inc).

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
哮喘和慢性阻塞性肺病——IQPC第二次会议。
国际质量与生产力中心(IQPC)第二届哮喘与慢性阻塞性肺病会议在费城举行,会议主题涵盖了哮喘和慢性阻塞性肺病领域的新治疗进展。本次会议报告重点介绍了针对哮喘的单抗治疗,包括靶向IL-5, IL-13, IL-9和TNFa, CCR3抑制剂,组胺H4受体抑制,新型COPD小鼠模型和吸入反义哮喘治疗。讨论的研究药物包括mepolizumab (GlaxoSmithKline plc), benralizumab (BioWa Inc . /Kyowa Hakko Kirin Co Ltd/MedImmune LLC), AMG-317 (Amgen Inc . /武田生物开发中心Ltd), TPI-ASM-8 (Pharmaxis Ltd)和AIR-645 (Altair Therapeutics Inc .)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Idrugs
Idrugs 医学-药学
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊最新文献
Neurodegenerative diseases. Edotecarin. Tesaglitazar. Anti-inflammatory drugs Alzheimer's Disease Drug Discovery--11th International Conference--Targeting Pathological Tau. 27-28 September 2010, Jersey City, NJ, USA.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1